Treatment or prevention of urogenital atrophy and its symptoms in women.

摘要

The use of the compound of formula (I) (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt thereof, or a metabolite thereof selected from the group consisting of TORE VI (4-hydroxy (deaminohydroxy) toremifene), TORE VII (4, 4 '' - dihydroxy (deaminohydroxy) - toremifene), TORE XVIII ((deaminocarboxy) toremifene), TORE VIII (4-hydroxy- (deaminocarboxy) toremifene) and TORE XIII (toremifene monophenol), for the manufacture of a pharmaceutical composition for the inhibition of urogenital atrophy in women, in which said urogenital atrophy is related to i) urinary symptoms selected from the group consisting of urination disorders, dysuria, hematuria, urinary frequency, a feeling of imperative need urination, urinary tract infections, urinary tract inflammation, nocturia, urinary incontinence, imperious incontinence and involuntary loss of urine, or ii) vaginal symptoms selected from the group that with It consists of irritation, itching, burning, smelly flow, infection, leukorrhea, vulvar pruritus, feeling of pressure and postcoital bleeding.